Navigation Links
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Date:7/15/2009

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins.

The agreement with CII provides Morphotek access to several of CII's monoclonal antibodies. Morphotek will evaluate one or more of the antibodies and have the right to exercise an option for a license during the evaluation period. Should Morphotek choose to exercise its option, the parties will enter negotiations for a license under which Morphotek would receive an exclusive worldwide license to develop the antibodies for potential therapeutic, diagnostic and prophylactic use, and would retain the responsibility for the commercialization of the antibodies.

"We are delighted that CII has decided to partner with Morphotek," said Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek. "We believe that these antibodies provide a novel approach to targeting tumor-associated proteins. Antibody targeting of tumor-associated proteins has demonstrated promising anti-angiogenic activity in preclinical studies. We are pleased to be able to access these antibodies for evaluation and possible development as we continue to grow our therapeutic antibody portfolio."

"CII has developed several monoclonal antibodies, peptides and small molecules with potential applications in the treatment of cancer and neo-vascular disorders," said Toni Gray, President and CEO of CII. "This agreement with Morphotek has the potential for the development of new drug candidates for cancer."

Morphotek will apply its antibody discovery technologies, including its pro
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that it ... May 7, 2008., The Company has scheduled a ... May 7, 2008, at 11:00 AM EDT. Interested investors ... minutes prior to the call. A replay of the ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
... LEXINGTON, Mass., May 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... Phase III extension study of SUPPRELIN(R) LA (histrelin ... of central,precocious puberty or early onset puberty, at ... This study evaluated the two-year,safety and efficacy of ...
Cached Biology Technology:NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 2Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 4Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... that the extremely hot, dry and windy conditions on Black ... rolls, -similar to streamers of wind flowing through the air ... the first of its kind to produce such detailed, high-resolution ... for future fire management and warning systems. The work ...
... is a project that will require the cooperation ... and individuals. The 2012 American Chestnut Summit will ... and industry professionals to share the current state ... reintroduction of this species to eastern forests. The ...
... New Rochelle, NY, August 7, 2012The global market value of ... once therapeutics are approved that actually change the course of ... (GEN). The current therapeutic market is valued at $3 to ... or address the symptoms but do not alter the underlying ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2GEN reports on recent progress in Alzheimer's research 2
Alexa Fluor 647 anti-mouse Qa-2...
... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: